Haematopoietic stem cells, or HSCs, reside primarily in the bone marrow and continuously replenish the body’s blood and immune systems. Their ability to self-renew and produce multiple blood-cell lineages makes them attractive targets for treating inherited blood disorders, immune deficiencies and some cancers. Yet those same properties make them challenging to manipulate. Conventional gene-editing therapies often require stem cells to be removed from a patient, edited in a laboratory and then returned after conditioning treatment has cleared space in the bone marrow. An effective method for editing HSCs directly in vivo could simplify this process and potentially broaden access to cell and gene therapies.

The delivery system at the centre of the study is the lipid nanoparticle, a microscopic assembly of fats that can encapsulate and transport nucleic acids. Lipid nanoparticles became widely known through messenger RNA vaccines, but their potential extends far beyond vaccination. They can protect fragile genetic payloads from degradation, enter cells after administration and release their contents into the cytoplasm. For gene editing, such particles can be used to carry components that temporarily instruct a cell to cut, replace or regulate a selected DNA sequence. Unlike integrating viral vectors, many lipid-nanoparticle systems deliver their payload without permanently inserting a carrier genome into the recipient cell.

The major obstacle is specificity. When administered in the body, nanoparticles encounter proteins, membranes and immune cells throughout the circulation. Particles that accumulate in the liver, for example, may be highly effective for hepatic therapies but poorly suited to reaching bone-marrow stem cells. The researchers therefore developed targeted lipid nanoparticles intended to recognise and enter human HSCs more efficiently. Targeting can be achieved by displaying molecular ligands on the particle surface that bind receptors enriched on the desired cell type. Once attached, the particle may be internalised through receptor-mediated uptake, creating a route for the editing cargo to reach the cell’s interior.

This distinction between delivery and editing is crucial. A gene-editing system can be extraordinarily precise at the molecular level and still fail as a therapy if too little of it reaches the correct cells. HSCs represent only a small fraction of the cells in bone marrow, and they are surrounded by stromal cells, mature blood cells and other progenitors. A targeted particle must navigate this complex tissue, avoid premature clearance and release enough editing material inside the stem cell to generate a useful level of modification. At the same time, excessive exposure could damage cells or increase unintended editing, making the balance between potency and safety central to the design.

The study’s significance lies in its focus on human HSC biology rather than on delivery to a more accessible tissue. Editing these cells could have effects that persist for years because a successfully modified stem cell can divide and produce descendants across the blood system. That creates the possibility of correcting mutations at their source rather than repeatedly treating the symptoms produced by defective blood cells. It also raises the bar for safety: an alteration introduced into a long-lived stem-cell population could be inherited by many daughter cells, so researchers must evaluate both the intended genetic change and the possibility of unwanted genomic alterations.

Targeted lipid nanoparticles could offer several practical advantages over viral delivery platforms. Viruses have been engineered into powerful gene-transfer vehicles, but their manufacture, immune recognition, cargo limits and potential for persistent genetic activity can complicate treatment. Lipid nanoparticles are generally assembled from synthetic or semisynthetic components and can be designed to release transient editing instructions. Their chemistry can also be adjusted, allowing researchers to modify particle size, surface charge, stability and tissue distribution. These features make them a flexible platform, although they do not eliminate the challenges of immune responses, manufacturing consistency or delivery outside the liver.

The work also points toward a broader shift in gene therapy: from editing cells outside the body toward programming therapeutic changes in their native niches. In an ex vivo procedure, scientists can select cells, measure editing efficiency and remove poorly performing or damaged cells before infusion. In vivo treatment offers no such easy screening step. The nanoparticles must therefore perform their targeting, uptake and payload release within the patient, and the resulting cell population must be assessed through molecular and functional tests. Demonstrating meaningful editing in human HSCs is consequently an important milestone, but it is only one stage on the path toward clinical application.

Before such a method can be used routinely, researchers will need to establish how consistently the particles reach stem cells across individuals, how long the edited cells persist and whether blood production remains normal. Studies must also examine off-target editing, inflammatory reactions, dose limits and the behaviour of edited cells over extended periods. Questions about delivery to different bone-marrow compartments, the effects of preconditioning and the ability to adapt the system to different disease-associated mutations will be equally important. The therapeutic promise of the platform will ultimately depend not only on editing efficiency, but on whether it can deliver durable benefit with a risk profile acceptable for patients who may otherwise require lifelong treatment.

The report by Luo, Zhu and Mitchell marks a notable advance in the effort to make in vivo HSC gene editing technically achievable. By combining cell-selective targeting with the adaptable chemistry of lipid nanoparticles, the researchers address the delivery problem that has constrained many gene-editing concepts. The approach does not yet remove the biological and regulatory hurdles facing in vivo stem-cell therapy, but it provides a framework for pursuing treatments that act within the bone marrow rather than relying entirely on laboratory manipulation. If future studies confirm precise, durable and safe editing, targeted nanoparticles could help transform inherited blood disorders from conditions managed over a lifetime into diseases corrected at the level of the stem cells that sustain the blood system.

Subject of Research: Targeted lipid nanoparticle delivery for in vivo gene editing of human haematopoietic stem cells

Article Title: Targeted lipid nanoparticles unlock in vivo human haematopoietic stem cell gene editing

Article References: Luo, Z., Zhu, A.T. & Mitchell, M.J. Targeted lipid nanoparticles unlock in vivo human haematopoietic stem cell gene editing. Nature Biomedical Engineering (2026). https://doi.org/10.1038/s41551-026-01770-z

Image Credits: AI Generated

DOI: 10.1038/s41551-026-01770-z

Keywords: lipid nanoparticles, haematopoietic stem cells, in vivo gene editing, gene therapy, targeted delivery, bone marrow, regenerative medicine, nanomedicine

Cystic fibrosis, a life-threatening genetic disorder, stems from mutations within the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR plays an essential role in facilitating chloride and water transport across epithelial cells lining the airways, thereby maintaining a thin mucus layer critical for lung health. Defective CFTR function results in abnormally thick and sticky mucus that traps pathogens, leading to recurrent infections and progressive lung deterioration. While current CFTR modulator drugs have transformed treatment paradigms for many patients, approximately 10% suffer from mutations that either preclude CFTR protein production or generate non-functional variants, rendering these therapies ineffective.

Addressing this unmet need, the UCLA team engineered a sophisticated non-viral delivery system employing lipid nanoparticles—a technology already celebrated for its role in mRNA vaccine rollout—to simultaneously ferry the full complement of molecular tools necessary for targeted genome editing. These lipid nanoparticles encapsulate the CRISPR gene-editing complex, bespoke guide RNAs that direct the machinery to the precise genomic locus, and a comprehensive DNA template encoding the complete, functional CFTR gene. This orchestrated delivery facilitates the insertion of a large genetic payload directly into the cellular genome, eliminating dependency on viral vectors that often pose manufacturing challenges, immunogenicity risks, and cargo size limitations.

The ability to package all required components, particularly an expansive gene such as CFTR, into a single lipid nanoparticle represents an unprecedented technical breakthrough. This modular platform not only streamlines manufacturing but also enhances flexibility for re-administration and adaptation for other genetic disorders implicating large genes. Testing in vitro on cultured human airway epithelial cells harboring severe CFTR mutations showed promising delivery efficiency, with 3–4% of cells successfully acquiring the healthy gene insert. Remarkably, despite this modest correction rate, functional assays revealed restoration of CFTR chloride channel activity reaching near-normal levels across the cellular population, exemplifying the profound physiological impact of even partial gene correction.

This outsized functional recovery owes much to the team’s strategic codon optimization of the CFTR gene. By redesigning the gene sequence without altering the encoded protein, the researchers maximized translational efficiency, elevating CFTR protein synthesis per corrected cell. This approach amplifies therapeutic benefit without necessitating correction of all affected cells, an insight that could redefine gene therapy thresholds and expectations. The collaborators at UCLA’s Donald Kohn laboratory were instrumental in developing this enhanced gene design, underscoring the interdisciplinary nature of the project.

Another critical advantage of this genome-integrating strategy is durability. By embedding the corrected gene within the DNA, cells and their progeny can sustain CFTR production over time, contrasting with transient mRNA therapies requiring frequent dosing. However, achieving lasting therapeutic outcomes relies on targeting airway stem cells, which reside deep within the lung epithelium and replenish the airway lining lifelong. These stem cells constitute a formidable delivery challenge, compounded by the lung’s robust defense mechanisms and the thick mucus characteristic of cystic fibrosis patients.

Although the current work represents a proof of concept, demonstrating successful packaging and functional gene insertion in vitro, physician-scientists involved emphasize the forthcoming hurdle of effective in vivo delivery. They envision refining lipid nanoparticle formulations and administration routes to penetrate mucus barriers and reach relevant progenitor cells. Success here could enable one-time or infrequent dosing regimens with lasting clinical benefits, fundamentally shifting cystic fibrosis therapy paradigms.

Importantly, by circumventing viral vector systems, this approach may offer substantial manufacturing scalability and cost reductions, potentially broadening access to gene therapies worldwide. The modular lipid nanoparticle platform lends itself to iterative optimization and customization, allowing for swift adaptation to diverse genetic diseases beyond cystic fibrosis, including other inherited respiratory conditions and disorders involving large, complex genes.

The UCLA team’s findings herald a transformative era in gene therapy, where precision editing paired with innovative delivery overcomes traditional obstacles of size, immunity, and delivery efficiency. While clinical translation demands careful navigation of biological and regulatory challenges, this work lays a formidable foundation for universal, mutation-agnostic genetic cures. For patients and families confronting devastating lung diseases refractory to existing treatments, these advances kindle genuine hope—rooted not in distant possibility, but in compelling scientific progress charting a path forward.

Subject of Research: Lipid nanoparticle-mediated gene editing for cystic fibrosis treatment
Article Title: Lipid Nanoparticle-Enabled Full-Gene Insertion Restores CFTR Function in Human Airway Cells
News Publication Date: Not specified
Web References: https://advanced.onlinelibrary.wiley.com/doi/full/10.1002/adfm.202502540
References: Study published in Advanced Functional Materials, UCLA Broad Stem Cell Research Center collaboration, Donald Kohn laboratory contributions
Image Credits: Adalia Zhou

Keywords

Gene editing, Lipid nanoparticles, Nanomaterials, Nanotechnology, Biomedical engineering, Respiratory disorders

The versatility of macromolecular carriers is one of their most significant advantages, allowing researchers to tailor these systems to enhance the efficacy of gene delivery. Through the careful design of polymers, researchers can achieve controlled release profiles, improve biocompatibility, and incorporate targeting capabilities. These enhancements can lead to better therapeutic outcomes with reduced side effects, positioning macromolecular carriers as a key player in the advancement of gene therapies.

In recent years, significant strides have been made in the development of natural polymer-based carriers, which are particularly appealing due to their biocompatibility and biodegradability. For example, chitosan, derived from chitin, exhibits pH-sensitive behavior that allows for reversible solubility transitions. This property has been exploited to enhance the stability of drug delivery systems and promote endosomal escape, which is critical for effective gene therapy. Innovations such as PEGylation and methylation have further improved the performance of chitosan-based nanoparticles, making them more effective at delivering genetic material to target cells.

Similarly, dextran has been modified to include cationic groups that enhance its ability to bind DNA. This cationic dextran can facilitate the co-delivery of various therapeutics, as demonstrated in studies where it was used to suppress the growth of triple-negative breast cancer through the simultaneous delivery of docetaxel, chloroquine, and siRNA. Such breakthroughs highlight the potential of natural polymers in creating multifunctional platforms for targeted therapies.

Hyaluronic acid (HA) is another natural polymer that has garnered attention due to its affinity for CD44 receptors that are often overexpressed in tumors. The negative charge of HA can extend circulation time and improve resistance to enzymatic degradation, thereby enhancing therapeutic efficacy. This has been exemplified in research where HA-chitosan nanoparticles successfully delivered PXDN siRNA to ovarian cancer cells, inhibiting angiogenesis. These findings not only underscore the importance of natural polymers but also signal a shift towards more biocompatible drug delivery systems.

On the synthetic side, cationic polymers such as poly(L-lysine) (PLL) and polyethylenimine (PEI) have been extensively researched for their efficiency in gene transfection. PLL can be modified to reduce cytotoxicity while still maintaining its ability to form effective DNA complexes. Research illustrating the combination of PLL with other polymers, such as chitosan, has demonstrated improved transfection rates, making it a compelling candidate for further investigation.

Polyethylenimine, with its high charge density, has shown exceptional capability in condensing DNA; however, it is often associated with cytotoxic effects. Recent innovations hold promise for mitigating these adverse effects while maintaining transfection efficiency. The development of cyclic amine-modified PEI has shown potential in reducing tumor invasion, thereby enhancing its therapeutic efficacy in clinical applications. Moreover, the incorporation of graphene oxide into PEI formulations has been found to simultaneously lower toxicity and boost transfection rates, indicating the potential for hybrid approaches that leverage the strengths of different materials.

Poly(β-amino esters) (PBAEs) have emerged as a biodegradable alternative with pH-responsive characteristics, enabling these polymers to respond to the acidic environment within endosomes. This responsiveness has made PBAEs a powerful tool, outperforming traditional polymers in plasmid DNA delivery to primary cells. The ongoing exploration of PBAEs signifies a growing interest in creating less toxic and more effective delivery vehicles for gene therapy applications.

Dendrimers and specialized polymer architectures such as star and comb polymers are at the forefront of innovation in gene delivery systems. Dendrimers, particularly polyamidoamine (PAMAM) dendrimers, possess hyperbranched structures that provide multiple functional surfaces conducive for gene loading. Research indicates that while high-generation dendrimers exhibit high delivery efficiency, their cytotoxicity poses challenges. Innovations such as ROS-responsive conjugation offer solutions to mitigate toxicity while maintaining functionality.

Star polymers represent another exciting approach in macromolecular design, providing a multi-armed configuration that enhances both gene loading and cellular uptake. Notably, studies have shown that star-shaped PEI-based polymers can achieve transfection rates significantly higher than those of their linear counterparts, emphasizing the importance of polymer architecture in optimizing gene delivery systems.

Functionalization with targeting ligands has become a focal point in enhancing the specificity of gene delivery. By incorporating peptides or antibodies that can selectively bind to receptors overexpressed in target cells, researchers have improved the efficacy of macromolecular carriers dramatically. For instance, RGD peptide-modified polyplexes have been shown to specifically target tumor integrins, while EGF-conjugated PAMAM dendrimers have demonstrated selective accumulation in EGFR-positive breast tumors. Such targeted strategies not only enhance the therapeutic potential of gene delivery systems but also minimize off-target effects, leading to safer treatments.

Despite the advances in macromolecular gene delivery systems, challenges remain. Cytotoxicity, variability in batch production, and suboptimal performance in vivo continue to hinder the clinical translation of these technologies. Addressing these limitations will be essential for the success of macromolecular carriers in gene therapy. Future strategies may involve the development of stimuli-responsive systems that can release their payload in response to specific environmental triggers, such as pH or redox potential. This spatiotemporal control can significantly enhance the therapeutic outcome, allowing for more precise interventions.

Hybrid carriers that combine the biocompatibility of natural polymers with the efficiency of synthetic designs present a promising avenue for future research. By blending these modalities, researchers can exploit the advantages of each type of polymer while mitigating their limitations. This synergistic approach could pave the way for the next generation of effective gene delivery systems, capable of addressing a broader range of therapeutic challenges.

The integration of nanotechnology in developing brain-targeting delivery systems holds immense potential for advancing gene therapy, particularly for disorders that require crossing the blood-brain barrier (BBB). Innovative nanoparticle designs that are capable of penetrating the BBB could open new therapeutic pathways for conditions such as neurodegenerative diseases, where traditional delivery methods fall short. As research continues to progress, these cutting-edge developments will undoubtedly play a crucial role in redefining the landscape of gene therapy.

Macromolecular systems are bridging vital gaps in gene therapy by offering innovative architectural designs and smart functionalization techniques. The future of this field lies in optimizing stability, scalability, and targeted delivery, with the ultimate goal of delivering clinically viable non-viral therapeutics. The advancements seen in the development of macromolecular gene delivery systems exemplify the exciting potential for non-viral vectors to transform the way we approach and treat genetic disorders, promising a new era of safer and more effective therapeutics.

Subject of Research: Macromolecular Gene Delivery Systems
Article Title: Macromolecular Gene Delivery Systems: Advancing Non-viral Therapeutics with Synthetic and Natural Polymers
News Publication Date: 25-Jun-2025
Web References: https://www.xiahepublishing.com/journal/jerp
References: http://dx.doi.org/10.14218/JERP.2025.00009
Image Credits: Rajaram Mohapatra

Keywords

Gene delivery, Gene therapy, Viral vectors, Drug delivery systems

Conventionally, CAR-T cell manufacturing relies heavily on viral vectors—typically lentiviruses or retroviruses—to deliver the CAR transgene into T cells ex vivo. While effective, viral vectors present considerable drawbacks including the risks of insertional mutagenesis, manufacturing complexity, batch variability, and exorbitant costs. Nanoparticle-based delivery systems circumvent many of these issues by offering a versatile, non-viral alternative for gene transfer. Engineered nanoparticles can encapsulate nucleic acids, such as mRNA or DNA plasmids encoding CAR constructs, and facilitate their cellular uptake through endocytosis or membrane fusion. This approach reduces the risk of genomic integration and oncogenic transformation while enabling scalable, reproducible manufacturing processes amenable to widespread clinical deployment.

The design of nanoparticles for CAR gene delivery is a masterful interplay of materials science, immunology, and bioengineering. Lipid nanoparticles (LNPs), inspired by the success of mRNA vaccines, are among the frontrunners due to their biocompatibility, ease of functionalization, and efficient endosomal escape capabilities. These LNPs can be precisely tailored to protect nucleic acids from degradation, enhance cellular uptake by T cells, and ensure release of cargo into the cytosol, where translation or nuclear entry occurs. Additionally, polymeric nanoparticles constructed from biodegradable materials such as poly(lactic-co-glycolic acid) (PLGA) or polyethyleneimine (PEI) offer customizable platforms for controlled gene delivery kinetics, further refining therapeutic efficacy.

Beyond gene delivery, nanoparticles can be engineered to serve as immunomodulatory agents that potentiate the in vivo function of CAR-T cells. Tumor microenvironments are notoriously immunosuppressive, deploying physical barriers and biochemical signals that can exhaust or inhibit CAR-T cells. Nanoparticles capable of co-delivering immune-stimulating agents, such as cytokines, checkpoint inhibitors, or metabolic modulators, directly to CAR-T cells or to the tumor milieu can dramatically enhance T cell persistence, proliferation, and cytotoxicity. Moreover, nanoparticles can be functionalized to specifically home to tumor sites or lymphoid organs to localize CAR-T cell activation, thereby minimizing systemic toxicity and off-target effects.

One of the most exciting frontiers in nanoparticle-assisted CAR-T therapy is the concept of in vivo CAR-T cell generation. Traditionally, CAR-T cells are produced ex vivo in highly specialized facilities, involving laborious processes of cell extraction, genetic modification, expansion, and reinfusion. Nanoparticles equipped to deliver CAR-encoding nucleic acids directly into circulating T cells within the patient’s body could obviate the need for cumbersome cell manufacturing infrastructure. This in situ reprogramming strategy harnesses targeted nanoparticles to selectively transfect T cells, enabling immediate production of functional CAR-T cells in vivo. The implications are profound: rapid treatment initiation, significant cost reduction, and broader accessibility to CAR-T therapies worldwide.

Nonetheless, achieving effective and selective in vivo transfection requires overcoming formidable biological barriers. Circulating nanoparticles must evade immune clearance, resist premature degradation, and traverse complex tissue architectures to reach T cells efficiently. Advances in “stealth” coatings using polyethylene glycol (PEG) and targeting ligands that recognize T cell surface markers (like CD3 or CD8) have shown promise in enhancing nanoparticle biodistribution and cellular specificity. Fine-tuning nanoparticle size, charge, and surface chemistry further optimizes delivery efficiency and therapeutic outcomes.

The safety profile of nanoparticle-based CAR-T therapies is paramount, particularly when considering in vivo applications. Unlike viral vectors, nanoparticles generally exhibit lower immunogenicity and cytotoxicity, reducing adverse immune responses. Nonetheless, off-target effects, unintended gene delivery to non-immune cells, and potential for inflammatory reactions necessitate rigorous preclinical evaluation. Engineering biodegradable nanoparticles that degrade into non-toxic byproducts within controlled timeframes adds an additional layer of safety assurance, ensuring temporary presence within the body.

Integrating nanoparticles with the expanding toolkit of gene editing technologies unlocks unprecedented possibilities for CAR-T cell enhancement. Nanoparticles can simultaneously deliver CRISPR-Cas9 components alongside CAR constructs to achieve site-specific genomic edits that improve CAR expression, prevent immune exhaustion, or confer resistance to immunosuppressive factors within tumors. This combinatorial approach promises CAR-T cells with superior persistence, specificity, and resistance profiles, poised to overcome refractory cancers and heterogeneous tumor landscapes.

Moreover, nanoparticles designed for multimodal imaging capability empower researchers and clinicians with real-time tracking and monitoring of CAR-T cells in vivo. By incorporating contrast agents or fluorescent dyes, nanoparticle platforms can report on biodistribution, expansion dynamics, and tumor infiltration of CAR-T populations. This capability enhances safety monitoring, facilitates dose optimization, and accelerates scientific understanding necessary for clinical translation.

The convergence of nanotechnology and CAR-T therapy is driving a paradigm shift not only in cancer treatment but broadly across cell and gene therapies. The modular nature of nanoparticle engineering allows rapid adaptation to evolving therapeutic targets, logic-gated CAR designs, and combination regimens. As clinical trials begin to validate these approaches, the promise of more accessible, safer, and efficacious CAR-T therapies is becoming an attainable reality rather than a distant aspiration.

In summary, nanoparticles have emerged as indispensable allies in revolutionizing CAR-T cell therapy. Their application spans pivotal facets: enabling non-viral gene delivery that surmounts viral vector limitations, enhancing the in vivo functionality of CAR-T cells within hostile tumor microenvironments, and pioneering the direct in vivo generation of CAR-T cells that democratize access to treatment. Coupled with innovations in gene editing, immunomodulation, and diagnostic imaging, nanoparticle-based strategies stand at the vanguard of a new generation of precision immunotherapies set to transform oncology.

While challenges remain—from optimizing delivery specificity to ensuring regulatory compliance—the momentum is undeniable. As multidisciplinary collaborations surge forward, nanoparticle-enabled CAR-T therapy represents a beacon of hope, promising to extend transformative cancer immunotherapy benefits to patients worldwide with unprecedented safety, efficacy, and convenience.

The future of oncology may well be written in the language of nanoparticles: minuscule vehicles wielding immense therapeutic power to reprogram the immune system and eradicate malignancies at their root. This synthesis of materials science, molecular biology, and clinical medicine exemplifies the extraordinary potential unlocked when frontiers of science collide, illuminating a path toward conquering cancer in ways previously unimaginable.

Subject of Research:
Applications of nanoparticles in CAR-T cell therapy focusing on non-viral gene delivery methods, enhancement of CAR-T cell in vivo efficacy, and in vivo generation of CAR-T cells.

Article Title:
Applications of nanoparticles in CAR-T cell therapy: non-viral manufacturing, enhancing in vivo function, and in vivo generation of CAR-T cells.

Article References:

Albalawi, Y.A. Applications of nanoparticles in CAR-T cell therapy: non-viral manufacturing, enhancing in vivo function, and in vivo generation of CAR-T cells. Med Oncol 42, 378 (2025). https://doi.org/10.1007/s12032-025-02928-6

Image Credits: AI Generated